Abstract：
The aim of this study is to evaluate the relationship between serum TLR (Toll Like Receptor) 4, 9 and Resolvin E1 levels and primary sarcopenia in geriatric patients and to compare the diagnostic accuracy of these biomarkers with the SARC-F score. A total of 88 patients aged 65 years and older were evaluated in the study. Comorbidities and geriatric syndromes were identified and patients with secondary sarcopenia were excluded. EWGSOP2 criteria were used as diagnostic criteria for sarcopenia and SARC-F questionnaire was used to find individuals at risk for sarcopenia. Serum TLR 4, 9 and Resolvin E1 levels were analyzed by ELISA. There were no significant differences between the two groups in terms of age and gender (p = 0.654 and p = 1.000, respectively). SARC-F, serum TLR 9 and Resolvin E1 were significantly higher in the sarcopenia group compared to the non-sarcopenia group (p < 0.001, p < 0.001 and p = 0.040, respectively). Statistically significant parameters were evaluated by multiple regression analysis. TLR 9 and SARC-F score were both found to be associated with sarcopenia in multivariate logistic regression analysis [Odds ratio (OR) 3145, (95%) confidence interval (CI) 5.9-1,652,888.3, p = 0.012; OR 4.788, (95%) CI 2.148-10.672, p < 0.001, respectively]. ROC curve analysis showed that the area under the ROC curve (AUC) for TLR 9 and SARC-F was 0.896 (p < 0.001) and 0.943 (p < 0.001), respectively. Although this study supports the use of the SARC-F questionnaire in daily practice, serum TLR 9 levels may be an alternative to SARC-F in cases where SARC-F is not feasible.
摘要：
这项研究的目的是评估老年患者血清TLR（Toll样受体）4、9和ResolvinE1水平与原发性肌少症之间的关系，并比较这些生物标志物与SARC-F评分的诊断准确性。该研究共评估了88名65岁及以上的患者。发现合并症和老年综合征，并排除继发性肌少症患者。使用EWGSOP2标准作为少肌症的诊断标准，并使用SARC-F问卷寻找有少肌症风险的个体。通过ELISA分析血清TLR4、9和ResolvinE1水平。两组之间在年龄和性别方面没有显着差异（分别为p=0.654和p=1.000）。SARC-F,与非肌肉减少组相比，肌肉减少组的血清TLR9和ResolvinE1明显更高（分别为p<0.001，p<0.001和p=0.040）。通过多元回归分析评估具有统计学意义的参数。多因素logistic回归分析发现TLR9和SARC-F评分均与肌肉减少症相关[比值比(OR)3145,(95%)置信区间(CI)5.9-1,652,888.3,p=0.012;OR4.788,(95%)CI2.148-10.672,p<0.001]。ROC曲线分析显示TLR9和SARC-F的ROC曲线下面积(AUC)分别为0.896(p<0.001)和0.943(p<0.001),分别。尽管这项研究支持在日常实践中使用SARC-F问卷，在SARC-F不可行的情况下，血清TLR9水平可能是SARC-F的替代方案。
